143 related articles for article (PubMed ID: 9545698)
21. Muramyl dipeptide-Lys stimulates the function of human dendritic cells.
Todate A; Suda T; Kuwata H; Chida K; Nakamura H
J Leukoc Biol; 2001 Nov; 70(5):723-9. PubMed ID: 11698491
[TBL] [Abstract][Full Text] [Related]
22. Morphological study on Mycobacterium bovis BCG Tokyo 172 cell wall skeleton (SMP-105).
Uenishi Y; Kawabe K; Nomura T; Nakai M; Sunagawa M
J Microbiol Methods; 2009 May; 77(2):139-44. PubMed ID: 19318051
[TBL] [Abstract][Full Text] [Related]
23. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
24. Necrotic inflammatory reaction induced by muramyl dipeptide in guinea pigs sensitized by tubercle bacilli.
Nagao S; Tanaka A
J Exp Med; 1985 Aug; 162(2):401-12. PubMed ID: 3926935
[TBL] [Abstract][Full Text] [Related]
25. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
26. Isolation and identification of arabinose mycolates of Cell Wall Skeleton (CWS) derived from Mycobacterium bovis BCG Tokyo 172 (SMP-105).
Uenishi Y; Kusunose N; Yano I; Sunagawa M
J Microbiol Methods; 2010 Mar; 80(3):302-5. PubMed ID: 20079769
[TBL] [Abstract][Full Text] [Related]
27. The biological activity of new tuftsin derivatives--induction of phagocytosis.
Wardowska A; Dzierzbicka K; Trzonkowski P; Myśliwski A
Acta Pol Pharm; 2006; 63(5):378-81. PubMed ID: 17357588
[TBL] [Abstract][Full Text] [Related]
28. A novel immunostimulator, N-[alpha-O-benzyl-N-(acetylmuramyl)-L-alanyl-D-isoglutaminyl]-N6-trans-(m-nitrocinnamoyl)-L-lysine, and its adjuvancy on the hepatitis B surface antigen.
Yang HZ; Xu S; Liao XY; Zhang SD; Liang ZL; Liu BH; Bai JY; Jiang C; Ding J; Cheng GF; Liu G
J Med Chem; 2005 Aug; 48(16):5112-22. PubMed ID: 16078831
[TBL] [Abstract][Full Text] [Related]
29. Reversal of T cell anergy in leprosy patients: in vitro presentation with Mycobacterium leprae antigens using murabutide and Trat peptide in liposomal delivery.
Sridevi K; Khanna N; Chattree V; Pal PC; Haq W; Rao DN
Int Immunopharmacol; 2003 Nov; 3(12):1589-600. PubMed ID: 14555284
[TBL] [Abstract][Full Text] [Related]
30. Calreticulin is a binding protein for muramyl dipeptide and peptidoglycan in RK13 cells.
Chen D; Duggan C; Reden TB; Kooragayala LM; Texada DE; Langford MP
Biochemistry; 2004 Sep; 43(37):11796-801. PubMed ID: 15362864
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
[TBL] [Abstract][Full Text] [Related]
32. [Evolution of IGRA researches].
Ariga H; Harada N
Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
[TBL] [Abstract][Full Text] [Related]
33. Experimental pulmonary cavity formation by mycobacterial components and synthetic adjuvants.
Yamamura Y; Maeda H; Ogawa Y; Hashimoto T
Microbiol Immunol; 1986; 30(11):1175-87. PubMed ID: 3807794
[TBL] [Abstract][Full Text] [Related]
34. Expression of costimulatory molecules (CD80, CD86, CD28, CD152), accessory molecules (TCR alphabeta, TCR gammadelta) and T cell lineage molecules (CD4+, CD8+) in PBMC of leprosy patients using Mycobacterium leprae antigen (MLCWA) with murabutide and T cell peptide of Trat protein.
Sridevi K; Neena K; Chitralekha KT; Arif AK; Tomar D; Rao DN
Int Immunopharmacol; 2004 Jan; 4(1):1-14. PubMed ID: 14975355
[TBL] [Abstract][Full Text] [Related]
35. Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation.
Moschos SA; Bramwell VW; Somavarapu S; Alpar HO
Vaccine; 2005 Mar; 23(16):1923-30. PubMed ID: 15734064
[TBL] [Abstract][Full Text] [Related]
36. [Synthesis and protective anti-infective action of anomeric lipophilic glycosides of N-acetylmuramyl-L-alanyl-D-isoglutamine].
Zemliakov AE; Tsikalova VN; Tsikalov VV; Chirva VIa; Mulik EL; Kaliuzhin OV
Bioorg Khim; 2006; 32(4):424-31. PubMed ID: 16909867
[TBL] [Abstract][Full Text] [Related]
37. [Synthesis of lipophilic and fluorescent derivatives of N-acetylmuramoyl-L-alanyl-D-isoglutamine].
Bogomolov OV; Golovkina IV; Shvets VI; Bovin NV
Bioorg Khim; 1993 Feb; 19(2):190-6. PubMed ID: 8498960
[TBL] [Abstract][Full Text] [Related]
38. [N-acetylmuramyl-L-alanyl-D-isoglutamine glycosides. Effect of glycoside center configuration and aglycone nature on biological activity].
Zemliakov AE; Tsikalov VV; Kaliuzhin OV; Kur'ianov VO; Chirva VIa
Bioorg Khim; 2003; 29(3):316-22. PubMed ID: 12845808
[TBL] [Abstract][Full Text] [Related]
39. Clinical Phase I investigation of intravenous oil attached mycobacterial components as immunotherapeutic agents.
Vosika G; Trenbeath T; Giddings C; Gray GR
Adv Exp Med Biol; 1983; 166():159-69. PubMed ID: 6650279
[TBL] [Abstract][Full Text] [Related]
40. [General concept of immunomodulators].
Nihon Rinsho; 1990 Aug; 48 Suppl():880-935. PubMed ID: 1700171
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
